查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2125248

微生物檢測：市場洞察、競爭格局和市場預測 - 2034 年

Microbiology Testing - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

概述：

  • 全球微生物檢測市場到2025年達到 63.5億美元，預計到2034年將達到 137.9億美元。
  • 受感染疾病蔓延、抗生素抗藥性威脅日益加劇、分子和自動化檢測技術不斷進步以及對食品和藥品安全日益關注等因素的推動，預計2026年至2034年預測期內，該市場將以 9.0%的CAGR成長。
  • 依產品細分市場來看，到2025年，設備細分市場佔 58%的市場佔有率，推動微生物檢測市場的發展。
  • 依檢測類型分類，細菌檢測領域在微生物檢測市場中佔據主導地位，到2025年佔市場佔有率的54%。
  • 依技術分類，到2025年，基於培養的檢測方法將主導微生物檢測市場，佔 46%的佔有率。
  • 依應用領域分類，臨床診斷領域在2025年主導微生物檢測市場，佔31%。
  • 依最終用戶分類，醫院和診斷檢查室領域在2025年主導微生物檢測市場，佔 40%的佔有率。
  • 到2025年，北美佔據微生物檢測市場最大的佔有率，達到 42%，但預計到2034年，亞太地區將實現最快的成長。

微生物檢測是指對檢體進行實驗室分析，以檢測、鑑定和定量引起感染疾病和污染的微生物，例如細菌、病毒、真菌和寄生蟲。它支持感染疾病的診斷和治療、抗菌素抗藥性的監測，以及食品、製藥和環境領域的安全保障。該市場依產品、檢測類型、底層技術、應用和運行環境細分。依產品分類，包括檢測設備、試劑和耗材，以及支援這些設備的軟體和服務。依檢測類型分類，可分為不同類型微生物的細菌檢測、病毒檢測、真菌檢測和寄生蟲檢測。依技術分類，從仍然是該領域基礎的傳統培養方法，到發展最快的尖端領域 - 分子診斷，以及補充免疫檢測和其他技術，應有盡有。依應用分類，包括臨床診斷、食品檢測、製藥和生物技術檢測以及環境檢測。依最終用戶分類，該市場包括醫院和診斷檢查室、製藥和生物技術公司、學術和研究機構以及食品飲料行業。推動該市場發展的因素包括感染疾病負擔日益加重、抗生素抗藥性威脅日益嚴重、快速分子診斷和自動化檢測的普及，以及食品和製藥行業日益嚴格的安全要求。

微生物檢測市場的主要市場促進因素

  • 感染疾病的流行和發病率不斷上升，以及疫情和流行病的反覆威脅，使得準確快速檢測病原體的需求日益成長。
  • 全球抗生素抗藥性威脅日益加劇，對快速病原體鑑定和抗生素敏感性測試的需求也隨之增加，這將為適當治療和合理使用抗生素提供指南。
  • 不斷的技術進步提高了檢測的速度、準確性和處理能力，包括分子診斷、檢查室自動化、質譜鑑定和人工智慧（AI）。
  • 這是由於人們對食品安全的日益關注以及更嚴格的監管。根據世界衛生組織（世衛組織）估計，每年約有6億人遭受食物中毒，其中大部分是由微生物污染引起的。
  • 在製藥和生物技術產業，對整個生產過程中的微生物品管、無菌檢測和環境監測的需求日益成長。
  • 醫療保健成本不斷上漲，診斷檢測設施的基礎設施也不斷擴大，尤其是在亞太地區的新興經濟體。
  • 由於人口老化和免疫力缺乏者人數增加，人們對感染疾病的易感性也隨之增加，導致對微生物檢測的需求更大。

推動微生物檢測市場成長的因素

市場促進因素

感染疾病率上升

微生物檢測市場的主要驅動力是感染疾病患者病率和發病率的不斷上升。這是因為檢測和鑑定引起感染的微生物是微生物檢測的核心目標，而感染疾病的負擔直接決定了其需求。從影響全球人口的地方性細菌、病毒、真菌和寄生蟲感染疾病，到臨床上常見的性行為感染、呼吸道感染疾病、血液感染疾病、胃腸道感染疾病和尿道感染感染，感染疾病持續不斷地產生對檢測和鑑定致病微生物的巨大需求。此外，近期全球疫情的反覆出現，進一步凸顯了微生物檢測和監測的戰略重要性。準確快速地檢測病原體對於感染疾病的診斷和治療、集體爆發的隔離和控制以及公共衛生監測非常重要，這使得微生物檢測成為醫療保健系統中不可或缺的一部分。人口成長和老化、免疫力缺乏低下人群增多、病原體的出現和再次出現，以及人們對感染疾病的認知和診斷水準的提高，都加劇了這一負擔，而這些因素也都促使檢測量增加。鑑於感染疾病的規模和持續性、不斷成長的負擔，以及微生物檢測在疾病防治中的重要性，這些因素為市場成長提供了最堅實的基礎。

抗生素抗藥性的威脅日益加劇。

全球日益嚴峻的抗生素抗藥性威脅是微生物檢測市場強勁且獨特的驅動力。這是因為快速且準確地鑑定病原體和進行抗生素敏感性測試對於應對抗藥性非常重要，而這些正是微生物檢測的核心功能。抗菌素抗藥性是指細菌、真菌和其他微生物進化出對治療藥物的抗藥性，它是全球公共衛生面臨的最嚴重威脅之一，世界衛生組織（WHO）和公共衛生機構已將其列為緊急優先事項。臨床和公共衛生應對抗藥性的措施依賴於微生物檢測，因為對抗藥性感染疾病進行適當治療需要識別致病微生物，並透過抗生素敏感性測試確定哪些抗生素仍然有效；目的是維持抗生素有效性的抗菌藥物管理計畫也依賴於微生物檢測提供的快速準確的診斷資訊。快速病原體鑑定和敏感性測試的需求，使臨床醫生能夠迅速從經驗性治療轉向標靶治療，這尤其推動了先進分子和自動化檢測方法的應用，這些方法比傳統培養方法能更快地提供結果。抗菌素抗藥性是一個大規模且不斷擴大的緊迫威脅，微生物檢測在應對這一威脅中發揮著核心作用，這使得該因素成為市場成長的強大而永續的驅動力。

市場限制因素

儘管感染疾病負擔沉重且日益加重，技術也快速發展，但微生物檢測市場仍面臨許多重大限制因素。其中最主要的限制因素是先進設備和自動化系統的高成本。分子診斷系統、質譜鑑定以及檢查室自動化系統的實施成本高昂，每個機構僅需數百萬美元的初步投資即可購買一套完整的檢查室自動化系統。對於新興市場的小規模區域醫院、獨立實驗室和醫療機構而言，這無疑是一道難以克服的障礙，而試劑和耗材的持續成本更是雪上加霜。如此高昂的成本使得只有資源雄厚的大型檢查室才能採用最先進的檢測方法，阻礙了新技術的普及。第二個限制因素是熟練的微生物學家和實驗室技術人員短缺。微生物檢測，特別是培養和藥敏試驗結果的解讀，以及先進分子診斷和自動化系統的操作，都需要專門的培訓，但合格人員的供應以及正規培訓項目的提供卻十分有限，這限制了檢測的處理能力和品質，尤其是在新興市場。第三個限制因素是傳統培養檢測耗時過長，而培養仍是該領域的基礎。培養需要數天才能得出結果，延誤了診斷和治療。快速分子診斷雖然克服了這個限制，但成本高昂，且無法完全取代培養。監管機構和臨床醫生仍然需要培養來獲得明確的藥物敏感性結果。其他限制因素還包括保險償付和檢查室預算方面的壓力、分子檢測項目的複雜性和成本、診斷設備的監管要求，以及世界許多地區檢查室基礎設施的不平衡。這些因素 - 成本、人員、週轉時間和基礎設施 - 共同造成了這樣一種局面：儘管成長強勁，但同時也面臨著許多實際的限制。

目錄

第1章 微生物檢測市場：簡介

  • 調查範圍
  • 市場區隔
  • 市場概覽

第2章 微生物檢測市場：執行摘要

  • 主要亮點和市場概覽

第3章 微生物檢測市場：關鍵因素分析

  • 市場促進因素
    • 感染疾病率上升
    • 抗生素抗藥性的威脅日益加劇
    • 分子檢測和自動化檢測的技術進步。
    • 人們日益關注食品安全問題，監管也日益嚴格。
  • 市場限制因素
    • 先進設備和自動化高成本
    • 熟練人員短缺
    • 使用培養法進行檢測所需時間較長。
  • 市場機會
    • 快速分子檢測與即時檢測
    • 新興市場和檢查室基礎設施

第4章 人工智慧、地緣政治、貿易與經濟趨勢

第5章 監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章 波特五力分析

第7章 微生物檢測市場：評估

  • 依產品
    • 裝置
    • 試劑和耗材
    • 軟體服務
  • 依測試類型
    • 細菌
    • 病毒
    • 真菌
    • 寄生蟲
  • 依技術
    • 使用培養方法的測試
    • 分子診斷
    • 免疫檢測
    • 其他
  • 依用途
    • 臨床診斷
    • 食品檢驗
    • 製藥和生物技術
    • 環境
  • 依最終用戶
    • 醫院/診斷檢查室
    • 製藥和生物技術公司
    • 學術研究機構
    • 食品飲料業
  • 依地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章 微生物檢測市場：競爭格局

  • 競爭分析
  • 企業市場占有率分析（加值服務）

第9章 微生物檢測市場：新創企業資金籌措與投資趨勢

第10章 微生物檢測市場：公司概況與產品概況

  • Thermo Fisher Scientific Inc.
  • bioMerieux SA
  • Becton, Dickinson and Company
  • Danaher Corporation（Cepheid）
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • Abbott Laboratories
  • QIAGEN NV
  • Bruker Corporation
  • Bio-Rad Laboratories, Inc.

第11章 KOL的觀點

第12章 專案方法

第13章 關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0990

Microbiology Testing Market Summary

Overview:

  • The global microbiology testing market was valued at USD 6.35 billion in 2025 and is projected to reach USD 13.79 billion by 2034.
  • The market is expected to expand at a CAGR of 9.0% during the forecast period 2026-2034, supported by the rising prevalence of infectious diseases, the growing threat of antimicrobial resistance, continuous technological advancement in molecular and automated testing, and increasing concerns over food and pharmaceutical safety.
  • By product, the instruments segment dominated the microbiology testing market with a 58% share in 2025.
  • By test type, the bacterial segment dominated the microbiology testing market with a 54% share in 2025.
  • By technology, the culture-based testing segment dominated the microbiology testing market with a 46% share in 2025.
  • By application, the clinical diagnostics segment dominated the microbiology testing market with a 31% share in 2025.
  • By end-user, the hospitals and diagnostic laboratories segment dominated the microbiology testing market with a 40% share in 2025.
  • North America accounted for the largest share of the microbiology testing market at 42% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

Microbiology testing is the laboratory analysis of samples to detect, identify, and quantify the microorganisms, including bacteria, viruses, fungi, and parasites, that cause infectious disease and contamination, supporting the diagnosis and treatment of infection, the surveillance of antimicrobial resistance, and the assurance of safety across food, pharmaceutical, and environmental applications. The market is organized by the product supplied, the type of test performed, the underlying technology, the application, and the setting of use. By product, it divides between the instruments that perform the testing and the reagents and consumables that they consume, together with the software and services that support them. By test type, it divides among the bacterial, viral, fungal, and parasitic testing that target the different classes of microorganisms. By technology, it spans the traditional culture-based methods that remain the foundation of the field, the molecular diagnostics that are its fastest-growing frontier, and the immunoassay and other methods that complement them. By application, it spans clinical diagnostics, food testing, pharmaceutical and biotechnology testing, and environmental testing, and by end-user it spans hospitals and diagnostic laboratories, pharmaceutical and biotechnology companies, academic and research institutes, and the food and beverage industry. The market is driven by the rising burden of infectious disease, the escalating threat of antimicrobial resistance, the migration toward rapid molecular and automated testing, and the stringent safety requirements of the food and pharmaceutical industries.

Microbiology Testing Market Key Growth Drivers

  • The rising prevalence and incidence of infectious diseases and the recurring threat of epidemics and pandemics, which drive the demand for the accurate and timely detection of pathogens.
  • The escalating global threat of antimicrobial resistance, which drives demand for rapid pathogen identification and antimicrobial susceptibility testing to guide appropriate therapy and stewardship.
  • Continuous technological advancement, including molecular diagnostics, laboratory automation, mass-spectrometry identification, and artificial intelligence, which improve the speed, accuracy, and throughput of testing.
  • Increasing concerns over food safety and stringent regulation, with the World Health Organization estimating that some 600 million people suffer foodborne illness each year, much of it from microbiological contamination.
  • The rising demand of the pharmaceutical and biotechnology industries for microbial quality control, sterility testing, and environmental monitoring across manufacturing.
  • Growing healthcare expenditure and the expansion of diagnostic laboratory infrastructure, particularly across the emerging economies of Asia-Pacific.
  • The aging of the population and the growth of the immunocompromised population, both of which increase susceptibility to infection and the demand for microbiological testing.

Key Companies in Microbiology Testing Market

The leading participants in the microbiology testing market include the following:

  • Thermo Fisher Scientific Inc.
  • bioMerieux SA
  • Becton, Dickinson and Company
  • Danaher Corporation (Cepheid)
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • Abbott Laboratories
  • QIAGEN N.V.
  • Bruker Corporation
  • Bio-Rad Laboratories, Inc.

Factors Contributing to the Growth of the Microbiology Testing Market

Market Drivers

Rising Prevalence of Infectious Diseases

The foundational driver of the microbiology testing market is the rising prevalence and incidence of infectious diseases, because the detection and identification of the microorganisms that cause infection is the central purpose of microbiology testing, and the burden of infectious disease directly determines the demand for it. Infectious diseases, from the endemic bacterial, viral, fungal, and parasitic infections that affect populations worldwide to the sexually transmitted, respiratory, bloodstream, gastrointestinal, and urinary tract infections encountered daily in clinical practice, generate a very large and continuing demand for the testing that detects and identifies their causative organisms, and the recurring threat of epidemics and pandemics, underscored by recent global experience, reinforces the strategic importance of microbiological testing and surveillance. The accurate and timely detection of pathogens is essential to the diagnosis and treatment of infection, to the isolation and control of outbreaks, and to the surveillance that protects public health, making microbiology testing an indispensable component of the healthcare system. The rising burden is driven by the growth and aging of the population, the expansion of the immunocompromised population, the emergence and re-emergence of pathogens, and the increasing recognition and diagnosis of infection, and each of these forces expands the volume of testing. Because infectious disease is a large, continuing, and rising burden, and because microbiology testing is essential to managing it, this driver provides the most durable foundation for market growth.

Escalating Threat of Antimicrobial Resistance

The escalating global threat of antimicrobial resistance is a powerful and distinctive driver of the microbiology testing market, because the response to resistance depends upon the rapid and accurate identification of pathogens and the testing of their susceptibility to antimicrobials, which is a core function of microbiology testing. Antimicrobial resistance, in which bacteria, fungi, and other microorganisms evolve to withstand the drugs used to treat them, is among the most serious threats to global health, and the World Health Organization and public health authorities have identified it as a priority demanding urgent action. The clinical and public health response to resistance rests upon microbiology testing, since the appropriate treatment of a resistant infection requires the identification of the causative organism and the determination of which antimicrobials remain effective against it through antimicrobial susceptibility testing, and the stewardship programs that seek to preserve the effectiveness of antimicrobials depend upon the rapid, accurate diagnostic information that microbiology testing provides. The demand for rapid pathogen identification and susceptibility testing, which allows clinicians to move quickly from empirical to targeted therapy, is a particularly strong driver of the adoption of the advanced molecular and automated testing that delivers results faster than traditional culture. Because antimicrobial resistance is a large, rising, and urgent threat, and because microbiology testing is central to the response to it, this driver is a powerful and durable contributor to market growth.

Market Restraints

Despite a large and rising burden of infectious disease and rapid technological advances, the microbiology testing market faces several material constraints. The most significant is the high cost of the advanced instruments and automation, since the acquisition of molecular diagnostic systems, mass-spectrometry identification, and laboratory automation is substantial, with total laboratory automation systems requiring upfront outlays of several million dollars per site, a hurdle that smaller community hospitals, independent laboratories, and providers in emerging markets struggle to clear, and the recurring cost of reagents and consumables adds to the total cost of ownership. This cost restricts the adoption of the most advanced testing to larger and better-resourced laboratories and slows the diffusion of new technology. A second constraint is the shortage of skilled microbiologists and laboratory technicians, since microbiology testing, particularly the interpretation of culture and susceptibility results and the operation of advanced molecular and automated systems, requires specialized training, and the limited availability of qualified personnel and of the formal training programs that produce them constrains both the capacity and the quality of testing, particularly in emerging markets. A third constraint is the slow turnaround of the traditional culture-based methods that remain the foundation of the field, since culture requires days to yield results, delaying diagnosis and treatment; although rapid molecular methods address this limitation, they carry higher costs and do not fully replace culture, which regulators and clinicians continue to require for definitive susceptibility results. Additional constraints include the pressure of reimbursement and laboratory budgets, the complexity and cost of the molecular testing menu, the regulatory requirements governing diagnostic devices, and the uneven laboratory infrastructure across much of the world. Together these cost, workforce, turnaround, and infrastructure factors ensure that growth, while strong, proceeds against genuine constraint.

Microbiology Testing Market Segment Analysis

The global microbiology testing market by product (instruments, reagents and consumables, and software and services), by test type (bacterial, viral, fungal, and parasitic), by technology (culture-based testing, molecular diagnostics, immunoassay, and others), by application (clinical diagnostics, food testing, pharmaceutical and biotechnology, and environmental), by end-user (hospitals and diagnostic laboratories, pharmaceutical and biotechnology companies, academic and research institutes, and the food and beverage industry), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Product

Dominant Subsegment: Instruments.

The instruments segment accounted for a 58% share of the microbiology testing market in 2025. The instruments segment dominates the product structure because the automated culture, identification, susceptibility, and molecular systems that perform microbiology testing represent substantial capital equipment, and their widespread adoption across clinical, food, pharmaceutical, and environmental laboratories anchors the market. The instruments span the automated blood culture systems, the identification and susceptibility systems, the mass-spectrometry identification platforms, the molecular and polymerase chain reaction systems, and the laboratory automation that together constitute the modern microbiology laboratory, and the value of these systems, together with the continuing transition toward automation and molecular testing, sustains the leading position of the segment. The reagents and consumables segment constitutes the second product category and the fastest-growing, comprising the culture media, test kits, panels, and other consumables that the instruments require, which generate recurring revenue tied to test volume and which grow as the installed base of instruments and the volume of testing expand, so that the reagents segment is anticipated to grow fastest over the forecast period as the razor-and-blade economics of the installed base assert themselves. The software and services segment completes the structure, comprising the laboratory information and analytics software and the service and support that the instruments require. The instruments segment is expected to retain its leading share throughout the forecast period, while reagents and consumables grow fastest.

By Test Type

Dominant Subsegment: Bacterial.

The bacterial segment accounted for a 54% share of the microbiology testing market in 2025. Bacterial testing dominates the test-type structure because bacterial infections are the most common and most clinically significant of the infections that microbiology testing addresses, and because the identification of bacteria and the testing of their susceptibility to antimicrobials constitute the core workload of the microbiology laboratory. Bacterial infections, from the bloodstream, respiratory, urinary, gastrointestinal, and wound infections encountered daily in clinical practice to the foodborne and environmental contamination monitored across industry, generate the largest volume of microbiology testing, and the central role of bacterial testing in the diagnosis and treatment of infection and in the response to antimicrobial resistance, which is predominantly a bacterial phenomenon, sustains the leading position of the segment. The identification of the causative bacterium and the determination of its antimicrobial susceptibility, which guides the selection of effective therapy, are the defining tasks of clinical microbiology, and the growth of antimicrobial resistance intensifies the demand for them. The viral segment constitutes a substantial and fast-growing category, expanded by the demand for the molecular testing of respiratory, gastrointestinal, and other viral infections and reinforced by the experience of recent pandemics, and the fungal and parasitic segments, while smaller, address the serious and opportunistic infections that particularly affect immunocompromised patients. The bacterial segment is expected to retain its leading share throughout the forecast period, while viral testing grows rapidly.

Microbiology Testing Market Region Analysis

Dominant Region: North America

North America accounted for a 42% share of the global microbiology testing market in 2025. The region is expected to account for the largest share of the global market, driven by the high prevalence and awareness of infectious disease and antimicrobial resistance, the strong adoption of advanced molecular and automated testing, well-developed reimbursement and healthcare infrastructure, stringent food and pharmaceutical safety regulation, and the presence and commercial strength of the leading diagnostics companies. The United States hosts a large and technologically advanced network of hospitals, reference laboratories, and diagnostic laboratories that perform a very high volume of microbiology testing and are early adopters of the advanced molecular, mass-spectrometry, and automation technologies that define the modern field, and the strong reimbursement environment and high healthcare expenditure support the investment these systems require. The region leads in the response to antimicrobial resistance, in the adoption of rapid syndromic and molecular testing, and in the stringent food and pharmaceutical safety regulation that mandates microbiological testing, and it is the principal market for the newest diagnostic technologies, which are frequently cleared and launched first in the United States. The strong presence of the leading diagnostics companies and the well-developed research and public health laboratory infrastructure reinforce the position of the region. The region is expected to retain its leading position throughout the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate in the microbiology testing market through 2034. The region is emerging as the principal growth engine of the market, propelled by very large populations, a high and rising burden of infectious disease, expanding healthcare access and diagnostic laboratory infrastructure, rising healthcare expenditure, and increasing food and pharmaceutical safety regulation across China, India, Japan, and Southeast Asia. The region combines the largest populations in the world with a high burden of the infectious diseases that microbiology testing addresses, and the expansion and modernization of diagnostic laboratory infrastructure, driven by rising incomes, expanding healthcare access, and growing public and private investment, is converting this burden into demand for testing. Governments and private providers are investing in the laboratories, instruments, and personnel required to perform microbiology testing, in the strengthening of public health and surveillance capacity following the experience of recent pandemics, and in the food and pharmaceutical safety testing that rising regulation and a growing manufacturing base require. China combines a very large population with a rapidly developing diagnostics industry and manufacturing base, India combines a very large population and infectious disease burden with a rapidly expanding diagnostic laboratory sector, and Japan combines an aged population with a sophisticated and advanced testing market. The coexistence of demand for both advanced and cost-effective testing creates opportunity for international and regional companies alike. Regional growth is expected to exceed the global average across every segment.

Regional Commentary

North America

North America leads on value and adoption, holding a 42% share in 2025. The region combines a high burden and awareness of infectious disease and antimicrobial resistance, strong adoption of advanced molecular and automated testing, well-developed reimbursement and infrastructure, stringent food and pharmaceutical safety regulation, and the commercial strength of the leading diagnostics companies. It leads in the response to antimicrobial resistance and in the adoption of rapid syndromic and molecular testing, and it is typically the first market for new diagnostic technologies. Near-term dynamics are shaped by the migration to rapid molecular and syndromic testing, laboratory automation, antimicrobial stewardship, and the response to emerging pathogens.

Europe

Europe is a large and sophisticated market, and the home region of several of the leading companies, including major in vitro diagnostics and life-science firms, and it combines well-developed healthcare systems, strong public health and surveillance infrastructure, and stringent food and pharmaceutical safety regulation with Germany, France, and the United Kingdom as principal markets. The region combines a substantial and aging population with generally supportive public healthcare and with a strong regulatory emphasis upon antimicrobial resistance, food safety, and pharmaceutical quality. The In Vitro Diagnostic Medical Devices Regulation shapes the pace of introduction of new diagnostic tests, and the region sustains a competitive and advanced market served by both global and regional participants.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by very large populations, a high and rising burden of infectious disease, expanding healthcare access and diagnostic laboratory infrastructure, rising healthcare expenditure, and increasing regulation. The modernization and expansion of laboratory infrastructure is converting the large infectious disease burden into demand for testing. China combines a very large population with a developing diagnostics industry, India combines a very large population and disease burden with a rapidly expanding laboratory sector, and Japan combines an aged population with an advanced testing market. Both international and regional companies are expanding across the advanced and cost-effective segments. Growth exceeds the global average across every segment.

Rest of World

The Rest of the World comprises the Middle East, Africa, and South America. The burden of infectious disease is high across all three, and the region carries a substantial and rising demand for microbiology testing. The Gulf states combine high healthcare investment with advanced laboratory infrastructure, and the larger Latin American markets, particularly Brazil, support established diagnostic laboratory sectors and growing adoption of advanced testing, together representing steady growth. Much of Africa carries a very high infectious disease burden but faces severe constraints in laboratory infrastructure, personnel, and funding, so testing capacity is concentrated in the larger urban, private, and public health laboratories, with substantial unmet need. Regional growth will be driven by the high disease burden, expanding healthcare access and laboratory infrastructure, strengthening public health capacity, and the availability of cost-appropriate testing.

Microbiology Testing Market Competitive Landscape

The global microbiology testing market is classified as Moderately Concentrated. The market is led by a group of large diversified diagnostics and life-science companies with broad instrument, reagent, and molecular portfolios, which hold significant combined share, complemented by specialized microbiology and molecular diagnostics firms. Competition centers upon the breadth and menu of the testing portfolio, the speed and accuracy of results, the degree of automation, the installed base and its recurring reagent revenue, integration with laboratory information systems, and increasingly upon rapid molecular and syndromic testing and the response to antimicrobial resistance. The competitive landscape is evaluated across the following dimensions:

  • Market concentration: Moderately concentrated, with a group of large diversified diagnostics and life-science companies holding significant combined share across the instrument, reagent, and molecular segments alongside specialized microbiology and molecular diagnostics firms, and with the installed base, menu breadth, regulatory capability, and scale of the leaders constituting a barrier to entry.
  • Leading players: Thermo Fisher Scientific, bioMerieux, and Becton Dickinson lead the broad microbiology market through extensive instrument and reagent portfolios, with bioMerieux a microbiology specialist leader, Danaher through Cepheid strong in molecular and point-of-care testing, Roche, Abbott, and QIAGEN strong in molecular diagnostics, Bruker in mass-spectrometry identification, and Merck KGaA and Bio-Rad in defined segments.
  • Geographic reach: The leading participants maintain global commercial, distribution, and service organizations, decisive because microbiology testing is a global market requiring local sales, service, and regulatory presence, while specialized firms reach broader geographies through distribution and regional manufacturers serve domestic and cost-sensitive markets, particularly across Asia-Pacific.
  • Product portfolio strength: Competitive advantage rests upon offering a broad menu spanning culture, identification, susceptibility, and molecular testing, upon the automation that improves throughput and addresses personnel shortages, and upon the installed base that generates recurring reagent revenue, with the leaders competing on the breadth and speed of their testing menus and specialized firms on a superior technology such as syndromic molecular panels or mass-spectrometry identification.
  • Pipeline strength: Development is concentrated in rapid molecular and syndromic panel testing, rapid antimicrobial susceptibility testing, mass-spectrometry identification, laboratory automation, point-of-care and near-patient testing, artificial-intelligence-enabled interpretation, and the expansion of test menus across clinical, food, and pharmaceutical applications.
  • Strategic partnerships: Collaboration spans partnerships between diagnostics companies and hospitals, laboratories, and public health agencies, the integration of testing with laboratory information and health information systems, co-development of assays and panels, and partnerships that extend menus and geographic reach.
  • M&A activity: Acquisition and consolidation have shaped the field, including the acquisition of molecular diagnostics, rapid testing, and automation capability by the diversified leaders, exemplified by the building of molecular and point-of-care portfolios, and the acquisition of specialized microbiology and technology firms to expand menus and capabilities.
  • Innovation focus: Innovation is shifting toward rapid molecular and syndromic testing that delivers results in hours, rapid antimicrobial susceptibility testing that accelerates targeted therapy, laboratory automation that addresses throughput and personnel constraints, point-of-care testing that extends microbiology beyond the central laboratory, and artificial intelligence in interpretation and workflow.
  • Regulatory standing: Regulatory clearance and approval for diagnostic devices in the major jurisdictions, including United States Food and Drug Administration clearance and CE marking under the In Vitro Diagnostic Medical Devices Regulation, is a decisive credential, and the stringent regulation of diagnostic, food safety, and pharmaceutical testing both raises the barrier to entry and rewards the scale and regulatory capability of the leading companies.

Microbiology Testing Market Recent Developmental Activities

In September 2025, bioMerieux received United States Food and Drug Administration clearance for anterior nasal swab testing on its BIOFIRE Spotfire platform, extending the Spotfire respiratory and sore-throat panel, a rapid multiplex polymerase chain reaction test that detects common viral and bacterial causes within fifteen minutes, to a more comfortable sample-collection method. Strategic significance: the extension of rapid near-patient syndromic testing to a more comfortable sample type reinforced the migration of microbiology testing toward fast, accessible, molecular point-of-care formats and the competition to bring syndromic testing closer to the patient.

Microbiology Testing Market Segmentation

Microbiology Testing Market Assessment by Product

  • Instruments
  • Reagents and Consumables
  • Software and Services

Microbiology Testing Market Assessment by Test Type

  • Bacterial
  • Viral
  • Fungal
  • Parasitic

Microbiology Testing Market Assessment by Technology

  • Culture-Based Testing
  • Molecular Diagnostics
  • Immunoassay
  • Others

Microbiology Testing Market Assessment by Application

  • Clinical Diagnostics
  • Food Testing
  • Pharmaceutical and Biotechnology
  • Environmental

Microbiology Testing Market Assessment by End-User

  • Hospitals and Diagnostic Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Food and Beverage Industry

Microbiology Testing Market Assessment by Geography

  • North America
  • United States Microbiology Testing Market Size in USD million (2023-2034)
  • Canada Microbiology Testing Market Size in USD million (2023-2034)
  • Mexico Microbiology Testing Market Size in USD million (2023-2034)
  • Europe
  • France Microbiology Testing Market Size in USD million (2023-2034)
  • Germany Microbiology Testing Market Size in USD million (2023-2034)
  • United Kingdom Microbiology Testing Market Size in USD million (2023-2034)
  • Italy Microbiology Testing Market Size in USD million (2023-2034)
  • Spain Microbiology Testing Market Size in USD million (2023-2034)
  • Rest of Europe Microbiology Testing Market Size in USD million (2023-2034)
  • Asia-Pacific
  • China Microbiology Testing Market Size in USD million (2023-2034)
  • Japan Microbiology Testing Market Size in USD million (2023-2034)
  • India Microbiology Testing Market Size in USD million (2023-2034)
  • Australia Microbiology Testing Market Size in USD million (2023-2034)
  • South Korea Microbiology Testing Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Microbiology Testing Market Size in USD million (2023-2034)
  • Rest of the World
  • Middle East Microbiology Testing Market Size in USD million (2023-2034)
  • Africa Microbiology Testing Market Size in USD million (2023-2034)
  • South America Microbiology Testing Market Size in USD million (2023-2034)

Key Takeaways from the Microbiology Testing Market Report Study

  • Market size analysis for the current microbiology testing market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
  • Key companies dominating the global microbiology testing market.
  • Various opportunities available for competitors in the microbiology testing market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current microbiology testing market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for microbiology testing market growth in the future?

Target audience who can benefit from this microbiology testing market report study

  • Microbiology Testing product providers
  • Research organizations and consulting companies
  • Microbiology testing-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in microbiology testing
  • Various end-users who want to know more about the microbiology testing market and the latest developments in the microbiology testing market.

Frequently Asked Questions:

Q1. At what rate is the microbiology testing market expected to grow?

The global microbiology testing market is projected to grow at a compound annual growth rate of 9.0% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the microbiology testing market?

On a DelveInsight-modeled basis, the global microbiology testing market was valued at USD 6.35 billion in 2025 and is projected to reach USD 13.79 billion by 2034.

Q3. Which region dominates the microbiology testing market?

North America dominated the microbiology testing market with a 42% share in 2025 on a modeled basis, driven by the high burden and awareness of infectious disease and antimicrobial resistance, strong adoption of advanced molecular and automated testing, well-developed reimbursement and infrastructure, stringent food and pharmaceutical safety regulation, and the presence of the leading diagnostics companies. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by very large populations, a high and rising burden of infectious disease, expanding healthcare access and diagnostic laboratory infrastructure, and increasing regulation across China, India, Japan, and Southeast Asia.

Q4. What are the key factors driving growth in the microbiology testing market?

The principal drivers are the rising prevalence of infectious diseases and the recurring threat of epidemics; the escalating threat of antimicrobial resistance, which drives demand for rapid pathogen identification and susceptibility testing; continuous technological advancement in molecular diagnostics, automation, and mass spectrometry; increasing food safety concerns and regulation, with the World Health Organization estimating some 600 million foodborne illnesses each year; the pharmaceutical and biotechnology demand for microbial quality control; growing healthcare expenditure and laboratory infrastructure; and the aging and immunocompromised populations.

Q5. Who are the major players in the microbiology testing market?

The market is moderately concentrated and led by Thermo Fisher Scientific Inc., bioMerieux SA, and Becton, Dickinson and Company, alongside Danaher Corporation through Cepheid in molecular and point-of-care testing, F. Hoffmann-La Roche Ltd., Merck KGaA, Abbott Laboratories, QIAGEN N.V., Bruker Corporation, and Bio-Rad Laboratories, Inc. Additional participants include Hologic, Inc., Agilent Technologies, Inc., NEOGEN Corporation, Shimadzu Corporation, DiaSorin S.p.A. (Luminex), and Charles River Laboratories.

Table of Contents

1. Microbiology Testing Market Introduction

  • 1.1. Scope of the Report
  • 1.2. Market Segmentation
  • 1.3. Market Overview at a Glance

2. Microbiology Testing Market Executive Summary

  • 2.1. Key Highlights and Market Snapshot

3. Microbiology Testing Market Key Factors Analysis

  • 3.1. Market Drivers
    • 3.1.1. Rising Prevalence of Infectious Diseases
    • 3.1.2. Escalating Threat of Antimicrobial Resistance
    • 3.1.3. Technological Advancement in Molecular and Automated Testing
    • 3.1.4. Increasing Food Safety Concerns and Regulation
  • 3.2. Market Restraints
    • 3.2.1. High Cost of Advanced Instruments and Automation
    • 3.2.2. Shortage of Skilled Personnel
    • 3.2.3. Slow Turnaround of Culture-Based Methods
  • 3.3. Market Opportunities
    • 3.3.1. Rapid Molecular and Point-of-Care Testing
    • 3.3.2. Emerging Markets and Laboratory Infrastructure

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1. The United States
  • 5.2. Europe
  • 5.3. Japan
  • 5.4. China

6. Microbiology Testing Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Microbiology Testing Market Assessment

  • 7.1. By Product
    • 7.1.1. Instruments
    • 7.1.2. Reagents and Consumables
    • 7.1.3. Software and Services
  • 7.2. By Test Type
    • 7.2.1. Bacterial
    • 7.2.2. Viral
    • 7.2.3. Fungal
    • 7.2.4. Parasitic
  • 7.3. By Technology
    • 7.3.1. Culture-Based Testing
    • 7.3.2. Molecular Diagnostics
    • 7.3.3. Immunoassay
    • 7.3.4. Others
  • 7.4. By Application
    • 7.4.1. Clinical Diagnostics
    • 7.4.2. Food Testing
    • 7.4.3. Pharmaceutical and Biotechnology
    • 7.4.4. Environmental
  • 7.5. By End-User
    • 7.5.1. Hospitals and Diagnostic Laboratories
    • 7.5.2. Pharmaceutical and Biotechnology Companies
    • 7.5.3. Academic and Research Institutes
    • 7.5.4. Food and Beverage Industry
  • 7.6. By Geography
    • 7.6.1. North America
      • 7.6.1.1. United States Microbiology Testing Market Size in USD million (2023-2034)
      • 7.6.1.2. Canada Microbiology Testing Market Size in USD million (2023-2034)
      • 7.6.1.3. Mexico Microbiology Testing Market Size in USD million (2023-2034)
    • 7.6.2. Europe
      • 7.6.2.1. France Microbiology Testing Market Size in USD million (2023-2034)
      • 7.6.2.2. Germany Microbiology Testing Market Size in USD million (2023-2034)
      • 7.6.2.3. United Kingdom Microbiology Testing Market Size in USD million (2023-2034)
      • 7.6.2.4. Italy Microbiology Testing Market Size in USD million (2023-2034)
      • 7.6.2.5. Spain Microbiology Testing Market Size in USD million (2023-2034)
      • 7.6.2.6. Rest of Europe Microbiology Testing Market Size in USD million (2023-2034)
    • 7.6.3. Asia-Pacific
      • 7.6.3.1. China Microbiology Testing Market Size in USD million (2023-2034)
      • 7.6.3.2. Japan Microbiology Testing Market Size in USD million (2023-2034)
      • 7.6.3.3. India Microbiology Testing Market Size in USD million (2023-2034)
      • 7.6.3.4. Australia Microbiology Testing Market Size in USD million (2023-2034)
      • 7.6.3.5. South Korea Microbiology Testing Market Size in USD million (2023-2034)
      • 7.6.3.6. Rest of Asia-Pacific Microbiology Testing Market Size in USD million (2023-2034)
    • 7.6.4. Rest of the World
      • 7.6.4.1. Middle East Microbiology Testing Market Size in USD million (2023-2034)
      • 7.6.4.2. Africa Microbiology Testing Market Size in USD million (2023-2034)
      • 7.6.4.3. South America Microbiology Testing Market Size in USD million (2023-2034)

8. Microbiology Testing Market Competitive Landscape

  • 8.1. Competitive Analysis
  • 8.2. Company Share Analysis (Premium Offering)

9. Microbiology Testing Market Startup Funding and Investment Trends

10. Microbiology Testing Market Company and Product Profiles

  • 10.1. Thermo Fisher Scientific Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Company Snapshot
    • 10.1.3. Financial Overview
    • 10.1.4. Product Listing
    • 10.1.5. Strategic Initiatives / Entropy
  • 10.2. bioMerieux SA
    • 10.2.1. Company Overview
    • 10.2.2. Company Snapshot
    • 10.2.3. Financial Overview
    • 10.2.4. Product Listing
    • 10.2.5. Strategic Initiatives / Entropy
  • 10.3. Becton, Dickinson and Company
    • 10.3.1. Company Overview
    • 10.3.2. Company Snapshot
    • 10.3.3. Financial Overview
    • 10.3.4. Product Listing
    • 10.3.5. Strategic Initiatives / Entropy
  • 10.4. Danaher Corporation (Cepheid)
    • 10.4.1. Company Overview
    • 10.4.2. Company Snapshot
    • 10.4.3. Financial Overview
    • 10.4.4. Product Listing
    • 10.4.5. Strategic Initiatives / Entropy
  • 10.5. F. Hoffmann-La Roche Ltd.
    • 10.5.1. Company Overview
    • 10.5.2. Company Snapshot
    • 10.5.3. Financial Overview
    • 10.5.4. Product Listing
    • 10.5.5. Strategic Initiatives / Entropy
  • 10.6. Merck KGaA
    • 10.6.1. Company Overview
    • 10.6.2. Company Snapshot
    • 10.6.3. Financial Overview
    • 10.6.4. Product Listing
    • 10.6.5. Strategic Initiatives / Entropy
  • 10.7. Abbott Laboratories
    • 10.7.1. Company Overview
    • 10.7.2. Company Snapshot
    • 10.7.3. Financial Overview
    • 10.7.4. Product Listing
    • 10.7.5. Strategic Initiatives / Entropy
  • 10.8. QIAGEN N.V.
    • 10.8.1. Company Overview
    • 10.8.2. Company Snapshot
    • 10.8.3. Financial Overview
    • 10.8.4. Product Listing
    • 10.8.5. Strategic Initiatives / Entropy
  • 10.9. Bruker Corporation
    • 10.9.1. Company Overview
    • 10.9.2. Company Snapshot
    • 10.9.3. Financial Overview
    • 10.9.4. Product Listing
    • 10.9.5. Strategic Initiatives / Entropy
  • 10.10. Bio-Rad Laboratories, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Company Snapshot
    • 10.10.3. Financial Overview
    • 10.10.4. Product Listing
    • 10.10.5. Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Global Microbiology Testing Market Size in USD million (2023-2034)
  • Table 2: Global Microbiology Testing Market Size by Product in USD million (2023-2034)
  • Table 3: Global Microbiology Testing Market Size by Test Type in USD million (2023-2034)
  • Table 4: Global Microbiology Testing Market Size by Technology in USD million (2023-2034)
  • Table 5: Global Microbiology Testing Market Size by Application in USD million (2023-2034)
  • Table 6: Global Microbiology Testing Market Size by End-User in USD million (2023-2034)
  • Table 7: Microbiology Testing Market Size in North America in USD million (2023-2034)
  • Table 8: Microbiology Testing Market Size in the United States in USD million (2023-2034)
  • Table 9: Microbiology Testing Market Size in Canada in USD million (2023-2034)
  • Table 10: Microbiology Testing Market Size in Mexico in USD million (2023-2034)
  • Table 11: Microbiology Testing Market Size in Europe in USD million (2023-2034)
  • Table 12: Microbiology Testing Market Size in France in USD million (2023-2034)
  • Table 13: Microbiology Testing Market Size in Germany in USD million (2023-2034)
  • Table 14: Microbiology Testing Market Size in the United Kingdom in USD million (2023-2034)
  • Table 15: Microbiology Testing Market Size in Italy in USD million (2023-2034)
  • Table 16: Microbiology Testing Market Size in Spain in USD million (2023-2034)
  • Table 17: Microbiology Testing Market Size in the Rest of Europe in USD million (2023-2034)
  • Table 18: Microbiology Testing Market Size in Asia-Pacific in USD million (2023-2034)
  • Table 19: Microbiology Testing Market Size in China in USD million (2023-2034)
  • Table 20: Microbiology Testing Market Size in Japan in USD million (2023-2034)
  • Table 21: Microbiology Testing Market Size in India in USD million (2023-2034)
  • Table 22: Microbiology Testing Market Size in Australia in USD million (2023-2034)
  • Table 23: Microbiology Testing Market Size in South Korea in USD million (2023-2034)
  • Table 24: Microbiology Testing Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Table 25: Microbiology Testing Market Size in the Rest of the World in USD million (2023-2034)
  • Table 26: Microbiology Testing Market Size in the Middle East in USD million (2023-2034)
  • Table 27: Microbiology Testing Market Size in Africa in USD million (2023-2034)
  • Table 28: Microbiology Testing Market Size in South America in USD million (2023-2034)
  • Table 29: Microbiology Testing Market Competitive Landscape
  • Table 30: Microbiology Testing Market Startup Funding and Investment Trends

List of Figures

  • Figure 1: Microbiology Testing Market Drivers
  • Figure 2: Microbiology Testing Market Restraints
  • Figure 3: Microbiology Testing Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis of the Microbiology Testing Market (the United States)
  • Figure 6: Regulatory Analysis of the Microbiology Testing Market (Europe)
  • Figure 7: Regulatory Analysis of the Microbiology Testing Market (Japan)
  • Figure 8: Regulatory Analysis of the Microbiology Testing Market (China)
  • Figure 9: Porter's Five Forces Analysis of the Microbiology Testing Market
  • Figure 10: Competitive Analysis of the Microbiology Testing Market
  • Figure 11: Global Microbiology Testing Market Size in USD million (2023-2034)
  • Figure 12: Global Microbiology Testing Market Size by Product in USD million (2023-2034)
  • Figure 13: Global Microbiology Testing Market Size by Test Type in USD million (2023-2034)
  • Figure 14: Global Microbiology Testing Market Size by Technology in USD million (2023-2034)
  • Figure 15: Global Microbiology Testing Market Size by Application in USD million (2023-2034)
  • Figure 16: Global Microbiology Testing Market Size by End-User in USD million (2023-2034)
  • Figure 17: Microbiology Testing Market Size in North America in USD million (2023-2034)
  • Figure 18: Microbiology Testing Market Size in the United States in USD million (2023-2034)
  • Figure 19: Microbiology Testing Market Size in Canada in USD million (2023-2034)
  • Figure 20: Microbiology Testing Market Size in Mexico in USD million (2023-2034)
  • Figure 21: Microbiology Testing Market Size in Europe in USD million (2023-2034)
  • Figure 22: Microbiology Testing Market Size in France in USD million (2023-2034)
  • Figure 23: Microbiology Testing Market Size in Germany in USD million (2023-2034)
  • Figure 24: Microbiology Testing Market Size in the United Kingdom in USD million (2023-2034)
  • Figure 25: Microbiology Testing Market Size in Italy in USD million (2023-2034)
  • Figure 26: Microbiology Testing Market Size in Spain in USD million (2023-2034)
  • Figure 27: Microbiology Testing Market Size in the Rest of Europe in USD million (2023-2034)
  • Figure 28: Microbiology Testing Market Size in Asia-Pacific in USD million (2023-2034)
  • Figure 29: Microbiology Testing Market Size in China in USD million (2023-2034)
  • Figure 30: Microbiology Testing Market Size in Japan in USD million (2023-2034)
  • Figure 31: Microbiology Testing Market Size in India in USD million (2023-2034)
  • Figure 32: Microbiology Testing Market Size in Australia in USD million (2023-2034)
  • Figure 33: Microbiology Testing Market Size in South Korea in USD million (2023-2034)
  • Figure 34: Microbiology Testing Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Figure 35: Microbiology Testing Market Size in the Rest of the World in USD million (2023-2034)
  • Figure 36: Microbiology Testing Market Size in the Middle East in USD million (2023-2034)
  • Figure 37: Microbiology Testing Market Size in Africa in USD million (2023-2034)
  • Figure 38: Microbiology Testing Market Size in South America in USD million (2023-2034)
  • Figure 39: Microbiology Testing Market Competitive Landscape
  • Figure 40: Microbiology Testing Market Startup Funding and Investment Trends